Limited Coverage Drugs – risedronate
|Generic name||Strength, form||Special Authority criteria||Approval period|
|risedronate||5 mg tablet or
35 mg tablet
Clinical or radiographically documented fracture due to osteoporosis
Glucocorticoid-induced osteoporosis in patients who are receiving or expected to receive the equivalent dose of 7.5 mg or more of prednisone per day for 90 or more consecutive days
|risedronate||30 mg||Diagnosis of Paget's disease||Indefinite|
- Patients who meet the above criteria for osteoporosis for risedronate automatically receive coverage for both alendronate and risedronate.
- Clinical fracture is defined as a symptomatic (painful) fracture.
- Radiographically documented fracture is defined as a fracture identified by x-ray (e.g., vertebral compression fracture). This may be asymptomatic.
- Coverage is intended for patients taking glucocorticoids with significant systemic absorption only (i.e., by oral or parenteral routes).
Special Authority requests